ABSTRACT: A major stimulus to study cell proliferation, particularly in rodent carcinogenicity assays and human tumors, has been the belief that the quantification of this fundamental biological process will provide the toxicologist and pathologist with objective data allowing a better understanding of the mechanisms involved in the toxicity and/or earcinogenicity of certain compounds as weil as guiding more effective management of patients afflieted with neoplasia. Among the markers used for cell proliferation measurement, PCNA has recently gained much attention and holds much promise as it is intricately involved in the cell replication processes. It not only eould allow measurement of the replication rates without necessitating pretreatment of the animalltissue in prospective studies, but also would allow retrospective assessment of the proliferative rates in archival tissues due to the conservation 01' this marker in fixed and paraffin-embedded tissues. Finally, knowledge of the function 01' PCNA in the cell cycle and its regulation by other factors may help us understand the advantages and !imitations 01' PCNA as a ceH proliferation marker in its application in toxicology and as a prognostic marker in human tumors.
I. INTRODUCTION
The fundamental biological process of cell division, and thus of cell proliferation, has been investigated from various viewpoints for a number of years. In the course of these investigations, numerous proteins intricately involved in the mechanism of cell division have been discovered. Among these, the proliferating cell nuclear antigen (PCNA/cyclin) has been most intensively investigated not only due to its role in DNA synthesis and DNA repair mechanisms, but also as a result of its use as a cell proliferation marker and particularly as a prognostic tooI in surgical pathology. Indeed, the existence of an endogenous cell proliferation marker that is preserved 1040-8444/93/$ .50 © 1993 by CRC Press, [ne. during tissue processing for pathological studies makes it tempting for toxicologists and pathologists to "go back" to studies that were completed some time in the past and measure retrospectively the cell proliferation rates resulting from the respective treatment regimens used in a particular study. However, the mere fact that this cell proliferation marker is a nuelear protein, the expression of which could be regulated by numerous factors and which may be involved in more than one mechanism of cell cyele control, should raise some doubt whether the "cell proliferation rates" measured via immunohistochemistry or flow cytometry can be taken as such without additional knowledge of the effects of the compound in question on the expression lev-eIs of PCNA or its regulating factors. Furthermore , although many lesions/tumors were shown to appear in conjunction with oncogene expression, growth factor overexpression or suppression, or loss oftumor suppressor genes, the question also must be raised whether these changes can influence PCNA expression levels and, if so, whether reliable .,cell proliferation rates" can be determined in these lesions/tumors with any degree of certainty. In addition, the designation PCNA/cyclin (i.e., cyclin due to the presumably cell cycle-dependent synthesis and marked presence during S-phase of PCNA) has caused confusion with the unrelated cyclins that have been described in frogs, clams, sea urchins, yeast, and mammalian cells. Thus, it is the intention of this paper to review the current literature on PCNA and to distinguish PCNA from other cell cycleassociated proteins with regard to its biochemical and molecular characteristics as weIl as to its function in the cell cycle. Moreover, the advantages and pitfaIls of current methodologies using PCNA as a cell proliferation marker in toxicology or as a prognostic tool in surgical pathology are discussed.
DISCOVERY OF PCNA IN HUMANS AND ITS PRESENCE IN OTHER EUKARYOTES
PCNA was first described by Miyachi et al. 1 as a nuclear antigen, restricted to proliferating cells, that reacts with sera from some patients with the autoimmune disorder systemic lupus erythematosus (SLE), hence the name proliferating cell nuclear antigen. Tested via indirect immunofluorescence, these sera reacted with proliferating cells in a variety of tissues of the mouse, rabbit, and human, as weIl as with the dividing cell populations of baby hamster kidney, mouse fibroblast, SP 2/0 mouse hybridoma, Wil-2 human B diploid lymphocyte, Hep-2 human hepatoma, MCF-7 human breast carcinoma, Raji, MOLT-4 T lymphocyte, and Ehrlich ascite tumor cells lines. 2 The presence of PCNA in various tissues and animal species, as previously mentioned, not only led to speculation as to the importance of this antigen, but also raised the question of its presence in other eukaryotes and 78 possibly prokaryotes. Indeed, the development of monoclonal antibodies to PCNA 3 and rat and human PCNA cDNA probes 4 -6 led to the discovery of PCNA-like proteins and homologous genes not only in eukaryotes, e.g., amphibians, mammals, marsupials, fish, birds, insects, ciliated protozoa, plants, and yeast,7-13 but also in viruses. 14 Furthermore , amino acid sequence comparisons between human and rat PCNA revealed an extremely high degree of homology,4-6 with only 4 amino acid substitutions in 261 amino acids. Moreover, it was shown that the yeast type of PCNA was able to functionaIly interact with mammalian DNA polymerase. 13 The presence of a similar PCNA gene throughout eukaryotes and, in some cases, viruses implies that a primordial gene for PCNA evolved more than one billion years aga at aperiod prior to the divergence into Planta and Animalia. 15 The latter observations also indicate that PCNA is, phylogenetically, a structurally and functionally highly conserved protein and thus, based on the concept introduced by Kimura and Ohta16 on the principles governing molecular evolution, PCNA must play an essential role in the cell cycle and in the maintenance of species. However, prior to discussing the function(s) of PCNA in the cell cycle, it is of utmost importance to define this protein biochemically and molecularly in order to clearly distinguish it from other cell cycle-associated proteins , i. e., the cyclins.
m. CHARACTERIZATION OF PCNA

A. Biochemical Characteristics
The gene for PCNA has been highly conserved throughout the course of evolution, as is quite impressively demonstrated by the fact that rat PCNA cDNA probes have been successfully used for the detection of homologous PCNA gene sequences in Xenopus laevis, Drosophila melanogaster, two subspecies of rice, soybean, and tobacco. 7 .
10 ,12 However, despite this high conservation, some differences are found in the DNA sequence and length ofthe gene coding for PCNA in the various species and genera. It is interesting to note that while in all genera there appears to be only one gene that codes for PCNA, disregarding the surpnsmg number of pseudogenes reported in mammalia whose function is not yet dear, the structure of the PCNA gene (DNA sequence and length and number of exons and introns) had undergone some modifications in the course of evolution among the genera, but has remained highly conserved within the respective genera, e.g., mammalia (Table 1) . 17 This may inlply that with increasing complexity of the higher organisms, an enhanced need for the control of cell division and differentiation and thus for the regulation of PCNA expression developed. Indeed, in higher eukaryotes such as D. melanogaster, rice (Oryza sativa), and mice, the 5'-flanking regions of the respective PCNA genes appear to contain homeodomain protein-binding sites in addition to the promoter region. 10, 17, 18 Homeodomain proteins have been shown to have a regulatory function in gene expression and to regulate via the modulation of important master genes, thus playing an important role in cell division and differentiation. 19 . 2o Furthermore, the presence of a similar number and nucleotide length of exons and introns in the PCNA gene of higher eukaryotes, namely, in the human and mouse PCNA gene,I7·21 as weIl as the observation that intron 4 of the human PCNA gene codes for that part in the PCNA protein necessary for the correct regulation of PCNA levels in quiescent cells,22 further corroborate the assumption that enhanced possibilities of regulating gene expression had to be developed concurrently with the increasing complexity of higher eukaryotes.
The PCNA gene product is a nuclear nonhistone protein , as demonstrated by Takasaki et al. 23 It was shown by Almendral and co-workers 4 to have a domain (amino acids 66-80) resembling the a-helix-tum-a-helix putative DNAbinding domain of several other DNA-binding proteins. 24 Generally, the PCNA faund in the various species are all acidic proteins; however, more acidic and more basic variants can be dis- tinguished. Currently two "variants " are weIl characterized: (1) an acidic variant found in humans, rat, hamster, and potoroo, with an isoelectric point (IP) of 4.5 to 4.8;25-27 and (2) the more basic variant found in the mouse. 27 Accordingly, these species-specific variants have different molecular weights (Table 1) . It is important to note that when the molecular weights are calculated according to the respective amino acid sequence, the resultant weights (Table 1) 13 Thus, the functional units of the latter PCNAs are comparable in molecular weight and size. In addition, the observation that calf thymus PCNA can stimulate yeast polymerase Irr, the mammalian polymerase 8 analog of the yeast Saccharomyces cerevisiae, or conversely that the yeast PCNA analog can stimulate the DNA-synthesizing abilities of calf thymus polymerase 8,13 emphasizes the apparent high conservation of PCNA in its structure and function throughout the course of evolution. This function is conserved despite the 80 fact that the amino acid sequence of the PCNAs found in mammals and yeast show very little homology. However, a sequence comparison between human, yeast, and baculovirus PCNA revealed that there are a few highly homologous domains, which might be important for proteinprotein interaction with the 8 polymerases. 34
B. Expression of PCNA during the Cell Cycle
In order to determine at what time point during the cell cycle PCNA synthesis is initiated, the PCNA content of synchronized cells, e.g., mouse 3T3 or human MOLT 4, was analyzed via immunofluorescence and flow cytometry, using monoclonal and/or polyclonal antibodies to PCNA.9.27.30.35-41 All investigators unanimously reported a maximum of staining intensity in the S-phase of cycling cells as weIl as the presence of PCNA at sites of ongoing DNA replication, as shown by the colocalization of PCNA and tritiated thymidine in the nucleus of replicating cells. 9 Further investigation showed that the concentration of PCNA increased starting in late GI phase, reaching its maximum during S-phase, which is approximately sevenfold the concentration found in quiescent cells,9,3o,35.38-41 and then to gradually decrease throughout O 2 phase and mitosis. Using a full-Iength cDNA clone for the human PCNA, these observations have further been corroborated by Almendral and co-workers 4 and laskulski and colleagues,42 who demonstrated that the expression of PCNA mRNA was low to undetectable in quiescent cells, whereas increased expression was detected 8 to lOh after serum stimulation of quiescent 3T3 cells, reaching a maximum induction of tenfold at 18 to 20 h, which also is the peak of DNA synthesis in these cells. In addition, quiescent cells stimulated with fetal calf serum in the presence of 5-hydroxyurea, thus being inhibited from DNA synthesis, exhibited the same increase in PCNA mRNA as control cells without hydroxyurea. These experiments suggested that the induction of PCNA mRNA expression is independent of DNA synthesis. 40 ,43 Despite the good rapport between PCNA detection via immunofluorescence and PCNA synthesis evidenced via mRNA leveIs, the findings by Bravo and MacDonaldBrav0 36 evoked some doubt as to the reliability of PCNA detection via immunofluorescence. Indeed, when cells were fixed using organic solvents such as methanol, PCNA was detected at the intranuclear sites where DNA synthesis was taking place as shown by simultaneous [3H]thymidine (Tdr) incorporation. 35 . 37 With this fixation technique, PCNA had a very granular distribution and was absent from the nucleoli in the early S-phase, whereas more prominent nucleolar staining was observed in the later stages of S-phase. On the other hand, when cells were fixed with aldehydes, the distribution of PCNA appeared different in that intense diffuse nuclear staining was observed throughout the cell cycIe. 36 This discrepancy was explained with the hypothesis that there are two forms of PCNA: an organic solvent insoluble form associated with the site of ongoing DNA synthesis, and a soluble form presumably not involved in DNA replication. 36 This hypothesis was substantiated further by Kurki and co-workers,43 who found higher numbers of formaldehyde-fixed cells staining positive for PCNA than for bromodeoxyuridine (BrdU). Furthermore, Morris and Mathews 44 demonstrated, in contrast to earlier studies, that the total concentration of PCNA varied at most two-to threefold during the cell cycle, but that a greater fraction of PCNA is insoluble due to chromatin association during S-phase than in other phases of the cell cycle, and, in corroboration with earlier findings by Bravo and MacDonald-Bravo,36 that a maximum of 30% of the PCNA present during S-phase was tightly associated with the nucleus and thus presumably present in replication complexes . Moreover, Morris and Mathews 44 concIuded that the cyclic synthesis of PCNA in proliferating HeLa cells maintained PCNA in excess of the amount necessary for DNA replication. If this were the case, the assessment of proliferating cells using the commercially available antibodies to PCNA 1 • 3 ,7,H,41,4S-4H would grossly overestimate the number of proliferating ceIls, as the antibodies apriori would not be able to distinguish between chromatin-associated and nonchromatinassociated PCNA. Indeed, Richter and coworkers 49 and Oaland and DegraefSO found an excellent agreement between cell proliferation measurements obtained via PCNA and Tdr or BrdU in tissues fixed with ethanol or methanol, whereas in tissues fixed with formalin or formaldehyde more PCNA than Tdr positive cells always were detected. 50 Coltrera and Gown,51 on the other hand, found no agreement or any correlation between the number of BrdU and PCNA positive alcohol-fixed cells in a variety of cell lines. However, prior to discussing the advantages and disadvantages of the various antibodies and the feasibility of using PCNA for cell proliferation studies, it is important to understand the regulation of PCNA mRNA expression and the function(s) of PCNA within the cell cycle.
As mentioned earlier, the levels of PCNA mRNA appear to be cycling during the cell cycle of 3T3 cells. 4 ,42 In these cells, the PCNA mRNA was shown to be inducible only by platelet-derived growth factor (PDGF), not by platelet-poor plasma. The expression of PCNA mRNA is inhibited by low concentrations of cycloheximide. 42 In addition, PCNA mRNA was not expressed in serum-stimualted ts 13 cells at the restrictive temperature,42,52 ts13 cells being 01-specific, temperature-sensitive mutants of the cell cycle originally derived from baby hamster kidney cells and made quiescent by serum deprivation. 42 The latter two findings suggest that the PCNA gene is growth factor regulated and, unlike early growth-regulated genes, PCNA requires the previous expression of other growthregulated genes (Figure 1 ). In contrast to other growth factor-regulated genes coding for proteins inherent to DNA synthesis, such as thymidine kinase, increased expression of PCNA mRNA can be induced by epidermal growth factor (BOF) or PDOP in the absence of other growth factors. 42 ,52 Gf the two most important pathways of regulating PCNA mRNA expression levels (Figure 1) , the transcriptional regulation of PCNA mRNA steady-state levels involving the promoter region and intron 4 of the PCNA gene 22 ,53 appears to playa minor role, whereas post-transcriptional regulation seems to predominate, as demonstrated in the latter experiments wherein the increase in mRNA levels that occurred in serumstimulated cells was largely post-transcriptionally regulated (Figure 1) 25 Within the concept of a two-polymerase hypothesis of eukaryotic replication, polymerase 0., with its tighly associated primase activity and semiprocessive mode of action, is ideally suited for the synthesis of the lagging strand. 60 Conversely, polymerase 0, lacking primase activity but possessing strand displacement activity and being highly processive in conjunction with the presence of PCNA,25,33 is capable of synthesizing long stretches of DNA as would be required of a leading strand polymerase (Figure 2) .60-f>3 This hypothesis was tested using the SV40 replication system and the tests showed that in the absence of PCNA the leading strand synthesis was virtuaIly abolished M -66 and that polymerase 0. was responsible for both the initiation and the synthesis of the lagging strand. Furthermore, leading strand synthesis was not inhibited when the SV40 replication system was treated with antibodies to polymerase 0.. 67 However, despite these clear indications that PCNA is direcdy involved in DNA synthesis and despite the fact that PCNA possesses a DNA-binding domain, no DNA-binding activities of PCNA could be detected. 25 Therefore, the role of PCNA in DNA synthesis appears to be the increased binding of polymerase 0 to poly(dA)/oligo(dT) in conjunction with the RF-A protein complex, RF-C protein complex, and activator 1 protein complex,65-68 resulting in the stabilization ofthe polymerase-template/primer complex ( Figure 2 ).
B. DNA Excision Repair
Besides the interaction of PCNA with polyluerase 8, PCNA can be detected in nuclei of non-S-phase cells following UV irradiation, suggesting an involvement of PCNA in the excision repair process.39,69 Inhibition of protein and DNA synthesis via cycloheximide and aphidicolin treatment, respectively, revealed that upon UV irradiation DO new PCNA was synthesized, the PCNA observed via immunofluorescence was redistributed from an already existing pool within the nucleus, and this immunofluorescence staining was independent of DNA synthesis, thus suggesting that the relocation of PCNA was not triggered by DNA repair synthesis by itself but possibly preceded it. 69 Furthermore, Toschi and Brav0 69 were able to show that the PCNA involved in excision repair was actually loosely attached to nuclear components and was in effect the part of the PCNA population that could not be detected in organic solvent fixed cells. In keeping with the hypothesis that the involvement of PCNA in the excision repair process precedes the actual DNA synthesis step, Shivji and coworkers 70 and Coverley and co-workers 71 investigated the excision repair process via fractionation of cell extracts and UV-irradiated plasmid DNA, which allowed them to resolve the excision repair process into discrete incision and polymerization stages. They were able to show that PCNA is required for the DNA synthesis that converts the nicked intermediates to complete repair events; however, this was only in conjunction with other proteins, e.g., xeroderma pigmentosum protein complement A (XP-A), human single-strand binding protein (HSSB), replication factor C (RF-C), and DNA polymerases 8 or E (Figure 3 ). However, with respect to excision repair, it must be stated that no direct interaction between PCNA and polymerase 0 has so far been demonstrated. On the contrary, Syvaoja and Linn 72 and Nishida and co-workers 73 described a PCNA-independent form ofpolymerase 8, which appeared to be involved in the DNA repair process in UV-exposed Brij-58 cells. The involvement of PCNA in DNA repair following UV irradiation and thus the detection of prior immunohistochemically undetectable PCNA forms must be taken into special consideration when using PCNA as a cell proliferation marker in epidermal tumors such as melanomas. In these tumors, immunohistochemical methods may weIl detect PCNA involved in DNA synthesis; however, not all PCNA positive cells need to represent dividing cells, meaning that a fair number of cells may be undergoing DNA repair. This applies not only to melanomas, as was shown to be the case, for example, in patients with acute myelogenous leukemia in which high levels of 84 PCNA correlated with DNA repair synthesis and was associated with enhanced resistance to chemotherapy but did not correlate with increased cell proliferation. 74 
c. Interaction with Tumor Suppressor
Genes and Oncogenes
From the previous paragraphs, it should be clear that PCNA is involved in two mechanisms inherent to the cell cycle, Le., DNA replication during the S-phase and DNA excision repair during the 02 phase and in quiescent cells. How- ever, in order to understand PCNA and its involvement in cell proliferation, it is necessary to understand not only how the expression of the PCNA gene and the level of the PCNA gene product are regulated, but also how PCNA gene expression and PCNA gene product levels may be affected by mutations, translocations, and allel loss in genes of cell proliferation and PCNA regulators.
Regarding altered PCNA RNA expression due to genetic events, constantly high expression levels ofPCNA mRNA and gene product have been found in continuously proliferating cells,44.54 indicating that the gene(s) downregulating PCNA expression has either been missing, nonfunctional due to alterations in the gene(s), or suppressed in its function by other proliferation regulators. Among the genes possibly regulating PCNA expression are the p53 and the retinoblastoma [pI05(Rb)] gene products. Both of these gene products have been shown to have tumor suppressing capabilities in that they can inhibit transformation of cells to tumorigenic phenotypes. 75 -79 Furthermore, it was shown that the two tumor suppressor gene products in their underphosphorylated state keep cells from progressing from the GI phase into S-phase, and thus play an important role in the control of the cell cycle (Figures 4 and 5) . Phosphorylation of these gene products by the cdc2(p34)-cyclinC complex lifts the G l-S-phase baITier, allowing transition of the cell into S-phase. 80 - 
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In view of the fact that PCNA is a late growth factor-regulated gene, its expression starting at / :; / wt-p53 ';1 "', tl! ..
FIGURE 4. Schematic model of the cyclic phosphorylation and dephosphorylation of the human wild-type p53 protein by the p34(cdc2)-cyclin complexes and phosphatases during the cell cycle. Although the p34-cyclin complex is depicted as the phosphokinase involved in the phosphorylation of p53 in every cell cycle phase, this has been explicitely shown to be the case for the p34-cyclin Bcomplex in only the G2-to M-phase transition. B4 However, p34-cyclin complexes have been implicated as the phosphokinase complexes involved in the G1-to S-phase, S-to G2-phase, and G2-to Mphase transitions in the human cell cycle. B5 The p53 protein is depicted here with three phosphate groups in the M-phase; however, the actual degree of p53 phosphorylation during the cell cycle has not been determined yet, with the exception that p53 is underphosphorylated in the G1 phase, phosphorylated upon entry into S-phase, and additionally phosphorylated during the transition from the G2-to the M-phase. 7B ,B4
In addition, the putative interaction possibilities of the DNA tumor virus gene products large T antigen (LTA) and adenovirus E1 B (E1 B) with the various p53 phosphorylation states are shown. 94 ,177 However, there is no evidence at this time that E1 B can bind to phosphorylated p53. The association of E1 B with phosphorylated p53 is merely hypothetical, and was drawn in analogy to the known association of the E1 A protein with phosphoryalted p105(Rb) depicted in Figure 5 . 82 ,17B the end of the GI phase (Figure 1 ), the question arises whether p53 and/or pI 05(Rb) have a regulatory effect on PCNA expression. Indeed, both p53 and pl05(Rb) have domains with DNA-binding abilities.
-
X9 However, thus far there is evidence only for the p53 gene product demonstrating that the wild-type p53 protein selectively downregulates PCNA mRNA and protein expression ( Figure 6 ) in conjunction with the inhibition 86 FIGURE 5 . Schematic model of the cyclic phosphorylation BO and dephosphorylation of the human p105(Rb) protein by the p34(cdc2)-cyclin complexes and phosphatases during the cell cycle. Although the p34-cyclin complex is depicted as the phosphokinase involved in the phosphorylation of p105(Rb) in every cell cycle phase, it has not been explicitely shown that cyclins are part of this phosphokinase complex implicated in p105(Rb) phosphorylation. However, the p34(cdc2) kinase has been implicated as the phosphokinase involved in p1 05(Rb) phosphorylation,179 and the p34-cyclin complexes have been shown to be important in the G-to S-phase, S-to G2-phase, and G2-to M-phase transitions of the human cell cycle. B5 The model also depicts the interaction possibilities of the DNA tumor virus gene products large T antigen (LTA) and adenovirus E1 A (E1 A) with the various p105(Rb) phosphorylation states.B2,178 of cell cycle progression. 90 Alteration of p53 by mutation, as often observed in human tumors, leads to gene products that are unable to bind to DNA,x6 thus raising the question whether mutated p53 can still regulate PCNA expression. Alteration or inactivation of p53 by mutation, or by its interaction with oncogene products of DNA tumor viruses, can lead to abrogated cell cycle control and subsequently to cancer. 77, 91 Although direct evidence is lacking, experiments with SV40 DNA virus-transformed keratinocytes show that PCNA expression is increased in these transformed cells, irrespective of the cell cycle stage, thus suggesting that the PCNA expression control by regulatory proteins is abrogated. 37 Furthermore, the conformational changes observed in the gene products of mutated p53 92 also could toxicological studies. Over/underestimation of cell proliferation could occur under circumstances in which PCNA protein is over/underexpressed as the result of functional changes in genes regulating PCNA expression. Indeed, overexpression of PCNA was found to con-elate with overexpression of wild-type and mutated p53 in human colorectal tumors. 102 Thus, more research studying tumor suppressor gene and oncogene expression in conjunction with PCNA (over/under)expression is clearly needed.
v. DIFFERENCES OF CYClIN(S) VS.
PCNA
Numerous publications describe a protein involved in the cell cycle as PCNAlcyclin; however, just this designation can be quite misleading inasmuch as PCNA and cyclin(s) are not one and the same, although both PCNA and cyclin(s) appear to be characterized by a cyclic expression during the cell cycle, have been highly conserved throughout evolution in many organisms, and seem to be intricately involved in ceIl replication. Of importance is that cyclins are synthesized during interphase, associate into a complex with the p34 cdc2 kinase (Figure 4 and 5), and are destroyed by cyclin-degrading enzymes after the ceIl enters S-phase (cyclins A, C, D, E), 02 phase (cyclins A), or mitosis (cyclins A and B).III.l13 Cyclin A was shown to playamajor role in the control of DNA replication in that the microinjection of mammalian cells with plasmids encoding antisense cyclin A cDNA or with affinity-purified anti-cyclin A antibodies during the GI phase led to inhibition of DNA synthesis. 114 Although it was demonstrated that the cyclin A_p33 cdk2 kinase complex, i.e., the p33 cdk2 kinase belonging to the p34 cdc2 kinase family, has a sequence-specific 88 DNA-binding activity, 115 this DNA-binding activity was associated with the phosphorylation of other DNA-bound substrates during S-phase (Figures 4 and 5 ) and was not, as is the case with PCNA, associated with the processes directly involved in DNA synthesis. Thus, cyclins are biochemically, structurally, and functionally different from PCNA and therefore the term PCNAI cyclin is erroneous and should be avoided.
VI. CEll PROLIFERATION MEASUREMENTS USING PCNA ANTIBODIES
There is increasing evidence that enhanced ceU proliferation, whether induced by chemicals, UV or ionizing radiation, or genetic alterations in cell cycle-regulating genes, may be a significant factor in the etiology of tumor development.116-120 Furthermore, the assessment of the rate of cell proliferation in an organ or lesion has been shown to be enormously useful for understanding at least some of the aspects of the underlying mechanisms involved in the development and progression of induced and spontaneously occun-ing lesions and tumors. 120-122 Thus, several methods for measuring cell proliferation, such as flow cytometry and immunohistochemistry, have evolved in the last few decades. Among these, methods using exogenously applied thymidine analogs (BrdU and 3[H]-thymidine [Tdr]) for marking the DNA synthesized during S-phase have seen widespread application and gained acceptance by the scientific community. However, the major disadvantages of these techniques is that postmortem (post-fixation) analysis of cell proliferation in organisms, organs, biopsies, or celliines is not possible without prior in vivo application of these S-phase markers. Thus, with the discovery of PCNA, with its presumably cyclic synthesis, involvement in DNA replication, and marked presence in S-phase cells, and the development of commercially available PCNA antibodies,I.3,41,46.48.123,124 much attention has focused on PCNA as a new marker for proliferating cells. In contrast to techniques using BrdU or Tdr, flow cytometric and immunohistochemical analysis using the endogenously formed PCNA could potentially allow retrospective assessment of cell proliferation in archived material. 125-127 However, in order to achieve reliable results with this new cell proliferation marker, it is not enough to understand the role and function of this endogenous protein in the cell, but rather a thorough knowledge of the possibilities, limitations, and uncertainties involved in the use of the techniques using this cell proliferation marker is aprerequisite.
A. Antibodies
As mentioned earlier, PCNA and the respective autoantibodies were discovered in patients presenting with SLE. These polyclonal autoantibodies were the first antibodies available for studying the role and function of PCNA. 1 ,7,8,27,38.41,55,123,124 In the beginning, the use of these polyclonal autoantibodies were problematic as these antibodies also recognized proteins other than PCNA.7,47 The preparation of a monospecific immunoglobulin G-type anti-PCNA via absorption of serum from an SLE patient to immobilized rabbit kidney extract, apparently eontaining negligible amounts of PCNA but abundant amounts of other autoantigens, solved the problem of unspeeific antigen reaetion.
3 ,7 In a further step, a number of monoclonal antibodies to PCNA were developed. 3 .46,48 Among these, three are commercially available: a murine IgM designated "19A2", a murine IgG designated " 19F4" , 3 ,46 and a genetically engineered murine IgG isotype designated "PCIO".48 Whereas the polyclonal PCNA autoantibodies were demonstrated to recognize at least two different epitopes at the N-and the C-terminals of the PCNA protein, the epitopes recognized by the 19A2 and 19F4 monoclonal antibodies appear to reside more to the center of the protein. 46 The PCI0 antibody was shown to have staining characteristics similar to those observed with the 19A2 and 19F4 antibodies when tested using immunofluorescenee,48 suggesting that the epitope recognized by PCI0 also may reside in the center of the protein. Epitope location and recognition by antibodies are important factors to be considered whenever PCNA is used as a eell proliferation marker. Indeed, Waseem and Lane 48 found that among their 11 genetically engineered PCNA antibodies one antibody (PC9) appeared to reeognize a completely discrete epitope, meaning that when monkey kidney CV-1 cells were stained with PC9 only the nucleoli were positIve for PCNA, thus suggesting that this specific epitope, not recognized by other PCNA antibodies, is present only on the nucleolar form and is absent or masked on the nucleoplasmic form of PCNA. This may indicate that the PCNA protein possibly undergoes conformational changes, depending on its location within the nucleus and its function during the cell cycle. On the other hand, these differences may reflect methodological discrepancies such as different fixation procedures, ete. The former hypothesis is corroborated by the observation that in studies in which the presenee of PCNA was measured in proliferating MOLT-4 cells via flow cytometry or immunofluorescence, polyclonal antibodies reacted with PCNA in cells from late GI to G2/M phase of the cell cycle,40,123 whereas the monoclonal antibodies 19A2 and 19F4 behaved more like S-phase markers. 41 The latter hypothesis is eontrasted by the observation that the monoclonal antibodies 19A2 and PCIO used for immunohistological deteetion of PCNA in fonnalin-fixed paraffin-embedded tissues were found to stain S-phase cells as weIl as cells undergoing mitosis. 45 ,128 Thus, with regard to the use of PCNA antibodies in cell proliferation measurement techniques, the question must be asked if indeed PCNA undergoes eonformational changes, and whether some of the epitopes may be masked during specific phases of the cell cyc1e and thus are not readily detectable by PCNA antibodies; or whether epitope masking is induced by the type of fixative used and the duration of fixation and thus represents a methodological artifact. Clearly, more studies, such as were commeneed by Waseem and Lane,48 are needed that are aimed at understanding changes in epitope aecessibility during the cell cycle. A possible future tool for such studies may be the use of a number of PCNA antibodies recognizing different well-characterized epitopes.
B. Methodologies (Figure 7 ), may vary depending on the methods used for tissue/cell preservation. Indeed, Garcia and co-workers 130 were not able to achieve acceptable staining in tissues fixed with formalin and embedded in paraffin, whereas tissues fixed with alcohol or methacarn proved to be no problem. Fixation-related differences in PCNA staining also were reported for immunofluorescence stainings (see Section III.B),35,36.4 3 ,137 where indeed it was postulated that different PCNA "forms" could be identified pending the use of either alcohols or aldehydes as fixatives. These findings were corroborated by Galand and Degraef,50 who found that tissue staining with the 19A2 antibody following methanol fixation would allow the detection only of S-phase cells, whereas in tissues fixed with aldehydes, the 19A2 antibody detected PCNA in cells of all phases of cell replication, with the exception of quiescent cells. On the other hand, Rowlands and co-workers, 138 using the PCIO antibody, found no differences in the degree of staining between sections fixed with absolute ethanol, methanol, Carnoy's fluid, 10% formol-saline, or 10% neutral buffered formalin; however, they were unable to achieve adequate staining in Bouin' s fixed sections. This stands in contrast to the findings by Hall and co-workers 45 and Dietrich and Curtis,133 who achieved accpetable staining with the PC 10 antibody in sections of Bouins' fixed human and rainbow trout tissues (Figure 8 ). To further confuse the matter, Hall and co-workers 45 found no PCNA immunoreactivity in normal liver sections assayed with the PCIO antibody, whereas Foley et al. , 125.128,139 Nakamura and co-workers, 140.141 and Dietrich and co-workersI26.132 found PCNA positive staining in liver seetions of normal and treated young and adult rats (Figures 7, 9 , and 10), mice,125 and rainbow trout 133 (Figure 8 ) using the I9A2 and the PCIO antibody, respectively. Unfortunately, not only the chaice of antibody and type of fixative used but also the duration of tissue fixation can influence the quality of the PCNA stain. Indeed, it was reported that staining in rat small intestine and human colon is greatly reduced after 48 h of fixation and is virtually abolished after 72 h,45 a trait that most likely can be explained by progressive protein-aldehyde crosslinking with increasing fixation time l42 and thus with protein conformational changes that consequently mask the PCNA epitopes. Therefore the study protocol plays a critical role with regard to PCNA immunohistochemical staining, and many of the discrepancies discussed previously may be related to study protocol differences as weIl as to the choice of PCNA antibody and staining pracedure.
Immunocytochemistry and Immunohistochemistry
a. Freshly Fixed Cells and Tissues
b. Archival Tissues
In view of the problems involved in the immunohistochemical detection of PCNA in recently fixed tissues, the question must be asked whether it is at all possible to do any retrospective cell proliferation studies in tissues that were fixed a lang time ago and in which the tissue fixation protocol usually is unknown or in tissues that have been kept in fixatives for years. PCNA staining was achieved in conventionally fixed and histologically processed archival human tissues, usually encompassing a 4-h formalin fixation and paraffin embedding, using both the PC10 135 ,I43 and 19A2 antibod y 130,l33,16 ( Figure 11 ) and a conventional staining procedure. 45 ,128,134 For tissues that were fixed for longer than 48 h, a special tissue treatment using the "Antigen Retrieval Solution ™ " (ARS) and microwaving was developed,126,127,132,140-142 making it possible to carry out PCNA immunostaining in tissues that had been preserved in formalin for up to 7 years (Figure 7) .126 It is hypothesized that microwaving the tissues in conjunction with ARS results in breaking the protein-aldehyde crosslinks and in recon- 92 stitution of the protein, thus unmasking the epitopes for PCNA immunohistochemistry ( Figures  7, 9 , and 10).142 Although different nuclear staining intensities possibly depicting the GO, G l-S, S, G2, and M phases of the cell cycle can be observed (Figure 7) , and despite the fact that it is generally accepted that the most intensive staining nuclei depict cells in S-phase whereas nonstaining cells represent quiescent ( 
Flow Cytometry
Flow cytometry is a method that enables the simultaneous quantitation of laser beam, xenon-, or mercury-arc-stimulated fluorescence of dyes and antibodies bound to cellular components in individual cells. This method has been successfully used for the distinction of cell cycle phases, i.e., by the determination of the amount of DNA present in the nucleus,146 an especially important factor that must be taken into consideration whenever cell proliferation is assessed in the liver where heptocytes, especially in rats and mice, are known to consist of several ploidy classes.145. the nuclear envelope during 02 and the coalescence of nucleoplasmic and cytoplasmic matrix during mitosis. 128 Oenerally, the highest PCNA cüntent was found in S-phase cells, at least in nüntransformed cell lines, whereas PCNA levels appeared to be high irrespective of the cell cycle phase in continuüusly proliferating HeLa cells.45 Thus, with regard to the cyclic variation ofPCNA cüntent, the agreement between the immunohistochemical, immunocytochemical, and flow cytometric analysis of proliferating cells, using PCNA antibodies, is generally good. The chief deficiency in the use of flow cytometry is the unavoidable loss of tissue architecture and the concomitant loss of information with respect to the anatomical distribution of cell proliferative activity. However, with the advent of techniques that allow flow cytometric analysis in tissues that had been conventionally fixed previously with formalin and embedded in paraffin, [149] [150] [151] fraction determined by flow cytometry was found in the gastrointestinallymphomas, 152 whereas no such correlation could be demonstrated for the gastric carcinomas153 or the hemangiopericytomas. 143 Indeed, such comparisons are extremely valuable in cases where an increased expression of PCNA is observed. However, no correlation of this expression to cell replication can be demonstrated, as was shown to be the case in human acute myelogenous leukemias,74 thus indicating that the increased PCNA expression in this case is possibly not related to its function in cell replicative DNA synthesis but rather to DNA ex-96 cision repair. One disadvantage of retrospective flow cytometry yet to be resolved is that at present is is possible to measure only the DNA content, not the PCNA content, in the cells of the respective tissue. The reason for this may be the fact that a pepsin digestion step is needed in order to render the tumor into the single cell moiety necessary for flow cytometric analysis, yet pepsin digestion as weIl as any other form of enzyme digestion has been shown to virtually abolish PCNA immunoreactivity. 45 In addition, to validate retrospective flow cytometric analysis in paraffin-embedded tissues with regard to cell proliferation assessments, it would be useful to compare the measured DNA contents to those of a simultaneously analyzed exogenously applied S-phase marker, such as BrdU. Although paraffin-embedded biopsy sampies of humans that had been treated with BrdU prior to biopsy are most likely not easily accessible, numerous sampIes from toxicology and carcinogenesis studies in rodents, all with well-defined treatment protocols, are obtainable and therefore would allOW the validation of cell proliferation measurements via retrospective flow cytometric analysis and its use in toxicology and pathology in conjunction with PCNA immunohistochemistry.
C. Comparison of Cell Proliferation
Measurement Using PCNA with Exogenous and Endogenous Cell Proliferation Markers Such As BrdU, Tdr, and Ki-67
Evaluations of PCNA as a cell proliferation marker via a comparison with the well-known and established exogenously applied cell proliferation markers Tdr and BrdU were carried out using immunocytochemistry on cultured cells grown on glass coverslips and on cytospins of cultured cells such as human amnion, mouse NIH 3T3, HeLa, MCF-7 human breast cancer, human peripheral blood mononuclear, human A-431 malignant carcinoma, human SK-5 nontransformed fibroblast, and HUVE (nontransformed human umbilical vein endothelial) cells. 36,.1X,45,51, 137 Not surprisingly, in synchronized cell cultures, the proliferation measured with PCNA and Tdr or BrdU correlated extremely weIl. 36,3H,45 However, comparative cell cycle analysis of PCNA and BrdU distribution in nonsynchronized MCF-7 cells indicated that replication patterns visualized by PCNA immunostaining were not a measure of replicative activity per se. 137 Similar observations were made by Coltrera and Gown,51 who found that the BrdU positive subpopulation of the SK-5 cellline was not identical to or had any overlap with the PCNA positive subpopulation. Interestingly, a coimmunostain with another endogenous cell proliferation marker, Ki-67, gave similarresults in SK-5 cells as did PCNA immunostaining, whereas this was not the case for the three other cell lines studied (Hela, A-431 , HUVE) . In two other cell lines (HeLa, A-431), the latter authors found that BrdU positive cells formed inclusive subsets of the PCNA positive population. This suggests that the PCNA expression levels may be different in cell lines with inherently different proliferation rates, and thus cannot uncritically be used as a marker for cell proliferation. This hypothesis was corroborated by Hall and co-workers,45 who demonstrated that the expression of PCNA remained constantly high and independent of the cell cycle phase in continuously proliferating HeLa cells.
Studies comparing cell proliferation measurements obtained via immunohistochemical staining of tissue sections with PCNA and BrdU, I Tdr, or Ki-67 have evolved recently and include freshly fixed as weIl as archi val tissues. 49 . 50 ,126,132,139-14I,I44,154-159 In freshly fixed rat colon, liver and kidney, and human colon, the agreement between cell proliferation measurements obtained via BrdU and PCNA appears to be excellent (Figures 9 and 10) ,49,140,141,157 especially if only S-phase cells were counted. Slightly higher labeling indices were obtained with PCNA in rodent and human liver and gastrointestinal tract;'56 however, this was shown to be the result of the counting procedure, i.e., all staining nuclei were counted, including non-Sphase cells. Similar results were reported by Galand and Degraef,50 who found the PCNA LI to markedly exceed the Tdr LI in formaldehydefixed tissue sections, whereas in methanol-fixed tissues, the PCNA LI agreed weIl with the Tdr LI. These differences are due mainly to the fact that in methanol-fixed sections primarily S-phase cells are PCNA positive, whereas in addition to the S-phase cells, non-S-phase cells stain positive in formaldehyde-fixed tissues (see Seetion VLB). Thus, cell proliferation measurements in freshly fixed tissues via PCNA immunohistochemistry appear to agree quite weIl with those obtained using the two weIl-known exogenously applied S-phase markers, BrdU and Tdr, and this suggests that PCNA immunohistochemistry is a viable method for cell proliferation measurement in freshly fixed paraffin-embedded tissues. Yet most of these studies mentioned were carried out in human tissues or in tissues of adult rodents , with the exception of the experiments carried out by Nakamura and co-workers,140,141 in which agerelated cell proliferation in liver and kidney was studied using PCNA and BrdU immunohistochemistry. These experiments showed that in animals aged 6 weeks and older there are no differences in PCNA LI and BrdU LI (Figures 9  and 10) . Surprisingly, the PCNA LI did not agree with those achieved with BrdU in the kidney and liver of male rats up to 6 and 4 weeks of age, respectively (Figures 9 and 10 ). Using the "Antigen Retrieval Solution™ " technique (ART) slightly improved the situation in that near agreement between PCNA LI and BrdU LI was achieved in rats as young as 2 weeks of age. However, these experiments indicate that PCNA may not be a suitable proliferation marker in very young animals. The reasons for this "underexpression" ofPCNA in very young animals certainly merits further investigation.
Comparisons between cell proliferation measurements via PCNA and BrdU immunohistochemistry or Tdr autoradiography also have been carried out using archival tissues. 126 ,132,139,158,159 All of these studies used rat or mouse liver tissues archived from earlier toxicological studies, with weIl-known treatment protocols, and the ART technique for improved PCNA immunohistochemieal staining. Among these tissues, some had been fixed very briefly, paraffin embedded, and then remained in paraffin blocks from 18 to 26 months (Table 2A) ,132,139,158,159 while others had been kept in the fixative for 7 years, paraffin embedded, and then remained in paraffin blocks for 18 months (Table 2B ).126 Generally, exeellent agreement was observed between S-phase PCNA LI and BrdU LI or Tdr LI irrespective of the duration of tissue fixation or paraffin storage, with the exception of one study in whieh the PCNA LI slightly exeeeded the LI determined via Tdr autoradiography (Table 2A) . This diserepaney may be explained by the low number of tissues analyzed and by the variability in staining intensities found to oeeur between and within treatment groups of the latter study, thus making a elear distinetion of S-phase from non-S-phase cells sometimes diffieult. 126 It has to be emphasized that in order to earry out retrospective eell proliferation measurements via PCNA immunohistochemistry it must be possible to distinguish clearly the S-phase from non-S-phase eells. However, despite the paueity of retrospeetive studies comparing PCNA with other cell proliferation markers, the present data indicate that PCNA is a suitable marker for retrospecitve cell proliferation measurelnent in arehival tissues.
PCNA immunohistoehemistry also was eorrelated to Ki-67 immunohistochemistry in human malignant lymphomas, 154 brain tumors, 160 and tumor xenografts of the LoVo cell line. 155 While good agreement between Ki-67 and PCNA was found in malignant lymphomas and low-grade gliomas, 154,160 little eorrelation to Ki-67 and growth fraction, estimated via fraction of labeled mitosis,155 was observed in astrocytomas, highgrade and mixed gliomas, Schwannomas, and xenograft tumors, 155.160 indicating that PCNA immunohistochemistry cannot be uncritically used as a proliferation marker in tumors.
VII. PERSPECTIVES, FUTURE NEEDS, AND APPLICATION OF PCNA AS A PROLIFERATION MARKER IN TOXICOLOGY AND AS A PROGNOSTIC MARKER IN SURGICAL PATHOLOGY
A. Toxicology
In its toxicological application, PCNA immunohistochemistry or, if even possibly, PCNA flow cytometry, should enable the measurement of cell proliferation in archival tissues thus preventing researchers from having to repeat eompleted studies currently lacking adequate proliferation data. So far, it has been established that PCNA may be used as a cell proliferation marker 98 as it compares quite weIl with other weIl-known S-phase markers such as BrdU or Tdr, and may reflect chemically induced cell proliferation even better than BrdU or Tdr especially if the proliferative index (PI), incorporating all PCNA positive cells, is used rather than the S-phase (LI). 158, 159 In addition, PCNA analysis has the potential to identify the specific cell populations (01, S, 02, M) that exist in the cell cycle and, if feasible, may lead to quantitating the effects of a compound on the different cell populations and thus to potentially critical information in understanding eompound-induced cell proliferation. 119 Indeed, the presence of cytoplasmic PCNA during the late 02 and M phase of the cell cycle 50 ,126.128 may provide further insight into the effects of chemicals on the distribution of PCNA within the eell during the cell cycle. However, for many tissues with a normally low proliferation rate, e.g., liver, kidney, pancreas, etc., the use of PCNA immunohistochemistry may prove to be problematic as only few cells will be positive for PCNA and of these very few will be in S-phase, meaning that the LIs generated with PCNA immunohistochemistry are more comparable to those generated by BrdU or Tdr administered as a pulse-dose rather than those from BrdU or Tdr administered continuously.139 Furthermore, in contrast to the exogenously applied proliferation markers BrdU or Tdr, the expression of PCNA, being a cell cycle-regulated protein, may be influenced by the compound the animal was treated with, indicating that PCNA immunohistochemistry eould under-or overestimate the actual proliferation rate. Indeed, the immunosuppressants dexamethasone and cyclosporin were shown to inhibit PCNA expression as weIl as T-lymphocyte proliferation, whereas the DNA synthesis inhibitors cytarabin and hydroxyurea prevented lymphoeyte proliferation but not PCNA expression. 43 Furthermore, Foley and coworkers l39 reported similar LI of PCNA and Tdr up to 24 h after 4-acetylaminofluorene (4-AAF) treatment; however, 48 h after 4-AAF treatment, the PCNA LI remained increased while the Tdr LI retumed to control values. These discrepancies could have stemmed from a potential induction of growth factors by the nongenotoxic 4-AAF resulting in the overexpression of PCNA (Figure 1) . Overexpression of PCNA also was reported in conjunction with poligeenan-induced colonic cell proliferation in F344 rats.!61 In this study, poligeenan, a nongenotoxic sulfated polysaccharide known to induce colorectal tumors, was fed in the diet for 64 days after which the animals were returned to the NIH-07 diet alone for 28 days. Despite removal of poligeenan from the diet, the PCNA levels in the upper third of the crypt remained ll-fold above control levels for 28 days, indicating either a decreased ability of the colon crypt cells to adapt rates of cell proliferation or a deregulated expression or catabolism of PCNA resulting from poligeenan treatment. Deregulation of the cyclic expression of PCNA was demonstrated earlier by Hall and co-workers,45 who found PCNA remained at high levels, irrespective of the cell cycle phase, in continuously proliferating HeLa cells. On the other hand, Ahnen and co-workers l62 found similar cell proliferation-associated staining patterns for PCNA and Tdr in normal colon and colonic tumors of rats treated with the known colon carcinogen dinlethlhydrazine, suggesting that in their study PCNA expression was a reliable marker of the proliferative compartment in the rat colon. Interestingly, the cell proliferative response was confined to the lower third of the crypt in the rectum, whereas in the proximal and mid-colon, staining extended into the mid to upper third of the crypt.
Regenerative cell proliferation determined with PCNA immunohistochemistry in mouse lung epithelia following acute injury with butylated hydroxytoluene l3 ! showed that the increased expression of PCNA correlated weIl with increased Tdr incorporation, indicating that PCNA expression is not altered during enhanced regenerative proliferation. Similarly, the effects of the mitogenic hepatocarcinogenic agents Wy-14, 643 and l,4-dichlorobenzene on liver cell proliferation were measured using PCNA and BrdU immunohistochemistry as weIl as Trd autoradiography!58,15lJ and demonstrated that mitogeninduced cell proliferation can be reliably determined with PCNA immunohistochemistry and that the two hepatocarcinogenic agents do not induce overexpression of PCNA.
However, in view of the paucity of data regarding compound-induced enhanced cell proliferation measured via PCNA analysis and keeping in mind that the expression of PCNA is regulated at several levels within the cell (Figure 1) , the questions need to be answered as to how and which genotoxic, mitogenic, and cytotoxic compounds (Figure 12) , hormones, and growth factors influence not only the expression of PCNA, but also the stability/half-life of PCNA mRNA and its protein product and thus the reliability of PCNA as a cell proliferation marker.
Such questions may be addressed by using a well-defined cell system, i.e., a cell line with a well-characterized and manipulatable cell cycle such as the Chinese hamster ovary cell, the V79 chinese hamster lung fibroblast, 146 or T lymphocytes,43 and combining flow cytometry, immunocytochemistry, and biochemical techniques (Western blot analysis, etc.) for PCNA analysis. Furthermore, these experiments should focus not only on the PCNA gene, mRNA, and gene product, but also on PCNA regulating factors such as p53, pI05(Rb), and TGF-ß (Figure 6 ), thus distinguishing between direct and indirect effects of compounds on PCNA expression. Indeed, with the development of techniques such as PCR and the availability of cDNA probes. for rat and human PCNA,5,6,21 it should be possible to analyze compound-induced alterations in the PCNA gene. Using these techniques, Liu and Bambara 54 demonstrated that PCNA is overexpressed in the R3230AC mammary tumor, which was accompanied by an altered PCNA gene structure. In addition, the experiments proposed earlier should be able to demonstrate whether an increased expression of PCNA is assoeiated with replicative DNA synthesis or DNA excision repair (Figures 2 and 3) . Although in vitro experiments, such as the ones proposed previously, are helpful in understanding the effects of compounds on a specific cell subpopulation of the cell cycle, they cannot replace studies in a whole tissue. Indeed, this is demonstrated by the study of Foley and co-workers,125 who found higher S-phase PCNA LI in liver foei of alteration than in the surrounding normal hepatocytes of control and methylene chloride-exposed female B6C3Fl mice, thus demonstrating a higher proliferative rate in the clonally expanded preneoplastic lesions. However, the combination of in vitro experiments with retrospective cell proliferation measurements in archival tissues of completed studies provides a powerful tool for studying the toxicity and/or carcinogenicity of the respective compounds. Furthermore, recent progress made in flow-cytometric analysis of archival tissues should allow distinguishing between PCNA associated with replicative DNA synthesis and PCNA involved in DNA excision repair, thus providing better insight into cell proliferation mechanisms and higher reliability of cell proliferation measurements.
Also, additional studies, e.g., analyzing cell proliferation measurement variability resulting from fixation, tissue handling, antibody, and staining procedure related effects, are required for the proper utilization and interpretation of the cell proliferation response as detected by PCNA analysis. Provided these studies are carried out and result in an improvement of in the methodology and a better data base, PCNA immunohistochemistry may prove to be the method of choice not only for retrospective but also for prospective studies. In view of recent reports regarding the adverse effects of the well-established cell proliferation marker BrdU, which suggest that BrdU may be toxic and therefore enhances the cell proliferative response, 163.164 these studies are urgently needed. Although most studies reported so far have been conducted in rodents and humans, PCNA immunohistochemistry and cytochemistry allow cell proliferation and cell cycle analysis to be conducted in a multitude of other organisms 7 ,S.1O-12,133 with the benefit that the findings all have the same denominator and thus are readily comparable. This also should make it possible to transfer the knowledge on toxic and carcinogenic mechanisms obtained in mammals to non-mammalian organisms important as bioindicators, such as fish or clams, for ecotoxicological risk assessment.
B. Surgical Pathology/Modern Medicine
The quest for more efficient management of patients afflicted with neoplasia and efforts to beUer predict the progression of tumors have led to a rather uncritical use of so-called prognostic markers in human tumors. Indeed, in many cases, such markers were readily applied without a clear understanding of the role or function of the marker 100 in the respective tumor. 165 Figure 11 ).134,135 Woosely and co-workers l34 ,135 statistically correlated the prognostic value of the proliferative fraction estimated via PCNA in melanomas with the clinical outcome (patient survival) and other prognostic indicators, e.g., anatomieal level, tumor thickness, mitotic frequency, tumor infiltrating 1ym-phocytes, tumor regression, or sex, and demonstrated that PCNA did not correlate to either the clinical outcome or any of the other prognostie indicators. Takahashi et al. ,136 on the other hand, compared the growth fraction visualized via PCNA immunohistochemistry with tumor grade only and found that PCNA-positive tumor cells increased in number and staining intensity with increasing progression of the lesions toward malignancy. To further understand the role of PCNA in melanomas, they exposed normal skin to sunlight, found that mainly suprabasal keratinocytes stained positive for PCNA whereas melanocytes were PCNA negative, and concluded that PCNA-positive staining in melanocytes was closely associated with malignant transformation. At first sight, the results of the studies by Woosley and co-workers 134 and Takahashi and co-workers 136 seem to contradict one another, but this need not necessarily be the case. The main problem lies in the assumption that all positive PCNA staining is associated with replicating activity; however, PCNA expression may be altered by changes in the structure of the PCNA gene, as was already shown to be the case in rat mammary tumors,54 and potentially has nothing to do with increased cell proliferation. Furthermore , increased PCNA-positive staining clearly not associated with cell proliferation also was observed in patients with acute myelogenous leukemia in conjunction with increased resistance to chemotherapy,74 in which case this increased PCNA expression was attributed to enhanced DNA excision repair. Indications of the latter observation also can be found in the study by Takahashi and co-workers 136 in that presumably increased cell proliferation-associated PCNA staining was observed in keratinocytes of the suprabasal layer but not in the basal layer of normal skin exposed to sunlight, although it is known that the basal celllayer is proliferatively active, thus indicating that some of the PCNA reactivity observed may have been due to DNA excision repair demonstrated to occur in cells irradiated with UV light (see Section IV.B).69.168 Therefore, PCNA immunostaining in melanomas may reflect a cohort of several "PCNA populations:" PCNA expressed as a function of cell replication, PCNA redistributed as a function of DNA excision repair, and PCNA over/underexpressed due to an alteration in the PCNA gene or deregulated PCNA transcription and translation. Deregulated PCNA transcription or translation also was suggested in cases where increased immunohistochemically detectable PCNA was observed in histopathologically nornlal breast lobules adjacent to breast tumors as weIl as in pancreatic exocrine parenchyma adjacent to endocrine and exocrine tumors of the pancreas. 45 In these cases, it was postulated that some of the tumors are actively secreting growth factors that are stabilizing the PCNA mRNA and thus inducing PCNA protein accumulation without actually inducing DNA synthesis. In this context, it also would be useful to analyze whether deregulated PCNA expression could stern from structural changes in the PCNA gene in these tumors, as was shown to be the case in rat matnmary tumors. 54 A further solution to this dilema may be the use of retrospective flow cytometry in conjunction with PCNA immunohistochemistry, thus distinguishing proliferating from nonproliferating cell populations. This approach was chosen by Woods and coworkers l52 in their evaluation of PCNA inlmunohistochemistry in primary gastrointestinallymphomas. Their study showed that there is a good correlation between the PCNA index and the histological grade of the tumors as weIl as a significant relationship between the PCNA index and the S +02 +M-phase fraction as measured by retrospective flow-cytometric analysis. A high PCNA index was significantly correlated with poor patient survival, thus indicating that a high PCNA index is an adverse prognostic factor in primary gastrointestinal tumors. Using the same approach, Jain and co-workers l53 and Yu et al. 143 evaluated the prognostic value of PCNA in gastric carcinomas and hemangiopericytomas, respectively. Although it was demonstrated that the PCNA index correlated weIl with patient survival probability in both retrospective studies, a positive correlation between PCNA index and histological grade was demonstrated only in hemangiopericytomas. In gastric carcinomas, the PCNA index did not correlate with histological grade, nor was there any correlation between PCNA index and tumor stage or lymph node metastasis. Furthermore, in both tumor types, the comparison between flow-cytometric measurement of cell proliferation and PCNA index, histological grade, or patient survival revealed that the results obtained with flow cytometry did not correlate with any of the latter parameters. Autocrine and paracrine growth factor-mediated regulation of PCNA expression also may explain the excess of PCNA immunoreactive cells observed in the above-mentioned tumors, indicating that not all PCNA staining observed in the different tumor types is functionally associated with cell replication, 160 thus emphasizing that PCNA immunohistochemistry in conjunction with retrospective flow cytometry may be a helpful tool for understanding tumor etiology and progression, but that the PCNA index should not be uncritically used as a prognostic marker.
PCNA immunohistochemistry also has been used to visualize regenerating hepatocytes in patients with acute viral hepatitis, hepatic cirrhosis, or hepatocellular carcinomas, 169 and to measure cell proliferation in hyperplastic, preneoplastic, and neoplastic lesions of intrahepatic bile ducts in livers with hepatoliths. 170 In the former study, the respective lesions were characterized by lesion-specific PCNA staining patterns and proliferation rates, while in the latter study it was shown that the PCNA LI increased with increasing malignant progression of the lesion, i.e., lowest in hyperplasias and highest in invasive adenocarcinomas. Simultaneous determination of the mean number of argyrophylic nucleolar organizer regions (AgNORs) demonstrated a significant positive correlation between PCNA LI and AgNORs count in alllesions, 170 thus suggesting that PCNA immunohistochemistry can be used for cell proliferation measurement in certain human tissues and lesions.
VIII. SUMMARY
The cell cycle-associated protein PCNA was reviewed here with regard to its regulation, expression, and function during the cell cycle as well as its use as a proliferation marker in toxicology and pathology and as a prognostic indicator in surgical pathology, i. e., patient management, particularly those afflicted with neoplasia. Despite numerous studies analyzing the function of PCNA in the cell, only two functions have been clearly elucidated to date, its association with replicative DNA synthesis and with DNA excision repair. Due to the varying expression levels and the varying distribution (10-calization) of PCNA during the cell cycle, it may be hypothesized that PCNA could have other functions besides the ones stated above. Future studies should focus on determining whether or not such additional functions exist. Moreover, additional studies are required that will provide data on the regulation/deregulation 01' PCNA expression by chemicals, hormones, growth factors, protooncogenes, and tumor suppressor genes. Only then will it be possible to adequately interprete the experimental data that used PCNA as a proliferation marker either by immunohistochemistry, immunocytochemistry, or flow cytometry. Furthermore, it will be necessary to understand and to be able to distinguish methodological effects related to tissue treatment, fixation, storage, and staining from compound-related effects on PCNA expression. However, despite these caveats, the present data clearly demonstrate that PCNA can be used for cell proliferation measurements in prospective as weIl as in retrospective studies. A more critical 102 approach must be taken for the use 01' PCNA as a prognostic marker in human tumors. The high variability 01' PCNA staining observed within tumors and among different tumor types limits its use as a prognostic marker per se for many tumor types. However, additional clinicopathological studies, whether prospective or retrospective, that encompass excellent patient selection, large numbers of patients, multiparameter analysis, documented clinical outcome, and comparable patient treatment protocols should be able to elucidate the role of PCNA in the context of human disease.
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